The BioFIND study: Characteristics of a clinically typical Parkinson's disease biomarker cohort

Identifying PD‐specific biomarkers in biofluids will greatly aid in diagnosis, monitoring progression, and therapeutic interventions. PD biomarkers have been limited by poor discriminatory power, partly driven by heterogeneity of the disease, variability of collection protocols, and focus on de novo, unmedicated patients. Thus, a platform for biomarker discovery and validation in well‐characterized, clinically typical, moderate to advanced PD cohorts is critically needed.

[1]  D. Vaillancourt,et al.  The NINDS Parkinson's disease biomarkers program , 2016, Movement disorders : official journal of the Movement Disorder Society.

[2]  D. Hernandez,et al.  Baseline genetic associations in the Parkinson's Progression Markers Initiative (PPMI) , 2016, Movement disorders : official journal of the Movement Disorder Society.

[3]  Nicholas Eriksson,et al.  NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases , 2015, Neurobiology of Aging.

[4]  J. Perlmutter,et al.  Neuroimaging biomarkers for Parkinson disease: Facts and fantasy , 2014, Annals of neurology.

[5]  H. Shill,et al.  Low clinical diagnostic accuracy of early vs advanced Parkinson disease , 2014, Neurology.

[6]  M. Farrer,et al.  Genetics and genomics of Parkinson’s disease , 2014, Genome Medicine.

[7]  Shengdi Chen,et al.  Salivary DJ-1 could be an indicator of Parkinson's disease progression , 2014, Front. Aging Neurosci..

[8]  D. Standaert,et al.  LRRK2 secretion in exosomes is regulated by 14-3-3. , 2013, Human molecular genetics.

[9]  Arthur W Toga,et al.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease. , 2013, JAMA neurology.

[10]  Peter Diggle,et al.  A longitudinal study on α-synuclein in blood plasma as a biomarker for Parkinson's disease , 2013, Scientific Reports.

[11]  Gan Wang,et al.  Proteomic Analysis of the Cerebrospinal Fluid of Parkinson's Disease Patients Pre- and Post-Deep Brain Stimulation , 2013, Cellular Physiology and Biochemistry.

[12]  J. Jankovic,et al.  How to identify tremor dominant and postural instability/gait difficulty groups with the movement disorder society unified Parkinson's disease rating scale: Comparison with the unified Parkinson's disease rating scale , 2013, Movement disorders : official journal of the Movement Disorder Society.

[13]  P. Auinger,et al.  Activity enhances dopaminergic long-duration response in Parkinson disease , 2012, Neurology.

[14]  R. Hays,et al.  Medication Responsiveness of Motor Symptoms in a Population-Based Study of Parkinson Disease , 2011, Parkinson's disease.

[15]  A. Singleton,et al.  The Parkinson Progression Marker Initiative (PPMI) , 2011, Progress in Neurobiology.

[16]  D. Goodlett,et al.  Salivary α-synuclein and DJ-1: potential biomarkers for Parkinson's disease. , 2011, Brain : a journal of neurology.

[17]  R. Margis,et al.  Identification of blood microRNAs associated to Parkinsonĭs disease. , 2011, Journal of biotechnology.

[18]  Brit Mollenhauer,et al.  α-Synuclein and tau concentrations in cerebrospinal fluid of patients presenting with parkinsonism: a cohort study , 2011, The Lancet Neurology.

[19]  Yu Wang,et al.  Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression , 2011, Annals of neurology.

[20]  R. Barker,et al.  Mild cognitive impairment in Parkinson disease , 2010, Neurology.

[21]  K. Marder,et al.  Frequency of known mutations in early-onset Parkinson disease: implication for genetic counseling: the consortium on risk for early onset Parkinson disease study. , 2010, Archives of neurology.

[22]  T. Kodama,et al.  Preparation and application of monoclonal antibodies against oxidized DJ-1. Significant elevation of oxidized DJ-1 in erythrocytes of early-stage Parkinson disease patients , 2009, Neuroscience Letters.

[23]  Helen M. Moore,et al.  2009 Biospecimen research network symposium: advancing cancer research through biospecimen science. , 2009, Cancer research.

[24]  J. Jankovic,et al.  Movement Disorder Society‐sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results , 2008, Movement disorders : official journal of the Movement Disorder Society.

[25]  W. Weber,et al.  Role of DAT‐SPECT in diagnostic work‐up of Parkinsonism , 2008, Movement disorders : official journal of the Movement Disorder Society.

[26]  Geert Mayer,et al.  The REM sleep behavior disorder screening questionnaire—A new diagnostic instrument , 2007, Movement disorders : official journal of the Movement Disorder Society.

[27]  K. Kashihara.  Weight loss in Parkinson’s disease , 2006, Journal of Neurology.

[28]  A. Lees,et al.  Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. , 2005, Brain : a journal of neurology.

[29]  J. Cummings,et al.  The Montreal Cognitive Assessment, MoCA: A Brief Screening Tool For Mild Cognitive Impairment , 2005, Journal of the American Geriatrics Society.

[30]  C. Tanner,et al.  Levodopa and the progression of Parkinson's disease. , 2004, The New England journal of medicine.

[31]  S. Fahn.  Description of Parkinson's Disease as a Clinical Syndrome , 2003, Annals of the New York Academy of Sciences.

[32]  M. Merello,et al.  Accuracy of acute levodopa challenge for clinical prediction of sustained long‐term levodopa response as a major criterion for idiopathic Parkinson's disease diagnosis , 2002, Movement disorders : official journal of the Movement Disorder Society.

[33]  Yoav Ben-Shlomo,et al.  The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. , 2002, Brain : a journal of neurology.

[34]  R. Barker,et al.  The heterogeneity of idiopathic Parkinson's disease , 2002, Journal of Neurology.

[35]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[36]  E. Corder,et al.  Stroke and Apolipoprotein E &egr;4 Are Independent Risk Factors for Cognitive Decline: A Population-Based Study , 2000, Stroke.

[37]  J W Langston,et al.  Parkinson disease in twins: an etiologic study. , 1999, JAMA.

[38]  A. Lees,et al.  A clinicopathologic study of 100 cases of Parkinson's disease. , 1993, Archives of neurology.

[39]  A. Lees,et al.  What features improve the accuracy of clinical diagnosis in Parkinson's disease , 1992, Neurology.

[40]  J. Jankovic,et al.  Variable expression of Parkinson's disease , 1990, Neurology.

[41]  W. Gibb,et al.  The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[42]  D. Standaert,et al.  LRRK 2 secretion in exosomes is regulated by 14-3-3 , 2013 .

[43]  W. Weiner,et al.  The clinically important difference on the unified Parkinson's disease rating scale. , 2010, Archives of neurology.

[44]  N. Kumar,et al.  Genotype–phenotype correlations between GBA mutations and Parkinson disease risk and onset , 2009 .

[45]  S Fahn,et al.  Committee. Unified Parkinson’s Disease Rating Scale. , 2001 .

[46]  A. Bonnet,et al.  [The Unified Parkinson's Disease Rating Scale]. , 2000, Revue neurologique.

[47]  S. Gilman,et al.  Diagnostic criteria for Parkinson disease. , 1999, Archives of neurology.

[48]  A. Lees,et al.  The clinical features of Parkinson's disease in 100 histologically proven cases. , 1993, Advances in neurology.

[49]  S. Fahn.  Members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale , 1987 .